about
Targeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon GammaPrevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.In Vivo Gene-Silencing in Fibrotic Liver by siRNA-Loaded Cationic Nanohydrogel Particles.New approaches for fibrosis regression in alcoholic cirrhosis.Dysregulation of redox pathways in liver fibrosis.Reversal of liver cirrhosis: current evidence and expectations.Sphingosine 1-Phosphate Signaling as a Target in Hepatic Fibrosis Therapy.Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.Reappraisal of Antihypertensive Medicine Doxazosin and Carvedilol as a Potential Therapeutic for Hepatic Fibrosis.Astragaloside IV synergizes with ferulic acid to suppress hepatic stellate cells activation in vitro.Endoplasmic reticulum oxidase 1α is critical for collagen secretion from and membrane type 1-matrix metalloproteinase levels in hepatic stellate cells.Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal.Optimized Mouse Models for Liver Fibrosis.Paired related homeobox protein 1 regulates PDGF-induced chemotaxis of hepatic stellate cells in liver fibrosis.The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice.Beneficial effects of naringenin in liver diseases: Molecular mechanisms.
P2860
Q26779055-88A57666-CDB0-4B9D-8407-AFE5AAD90716Q36279632-E89D7E08-D64B-4474-9AA6-93283C832B25Q38726399-A4BDD193-518D-4741-AE28-344FF4F9A0B5Q38815162-E7D8D71F-CD70-454F-AE86-067E94D9C2EEQ38909134-1D02F154-B38C-41F5-A360-4D729F6ED253Q38937340-A8E1AFCD-4C3C-49E7-B605-BBD779C5BC31Q38974002-FD394505-C134-4BD8-9D8E-E9659E15A0AEQ41547434-CEEB93D0-E8EB-4E51-B56B-6D905A1F7EF5Q42367659-0AD0C032-BE4E-4441-8E64-FD0FF2E5C097Q43112564-B7B252EA-4FC7-4EF9-B852-3C3FFEA22DC9Q46424713-558BA8DA-241A-4B5B-9479-6C0193273143Q47993214-FDB86810-8BB4-4EC1-B6E7-A4EB878B0963Q48242025-C703469D-2666-47EB-8775-0983F7F9BB17Q49792920-816371C4-B126-4897-A716-74AF9B7D91BFQ50219606-F2DA052D-3CD0-4045-81CC-D27D67748715Q50874486-7C0AA993-1F76-4B76-B7EF-712B5007D737Q51224682-475A230E-94AC-4C92-BC56-C65357312CF4Q54113356-67CA6AE3-5C31-40E2-8828-6F623CD7A95B
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Antifibrotic therapies in the liver.
@en
type
label
Antifibrotic therapies in the liver.
@en
prefLabel
Antifibrotic therapies in the liver.
@en
P2860
P356
P1476
Antifibrotic therapies in the liver.
@en
P2093
P2860
P304
P356
10.1055/S-0035-1550055
P577
2015-05-14T00:00:00Z